Advertisement

AVI BioPharma Inc. said Thursday it Michael D. Casey and Christopher S. Henney will not stand for re-election to the company's board of directors for personal reasons.

Their terms end in 2010.

AVI is developing treatments for Duchenne muscular dystrophy and viruses such as Ebola.

Shares fell 6 cents, or 4.1 percent, to $1.28 in premarket trading.

Advertisement
Advertisement